Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

MLA

Daniel P. Judge, et al. “Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (HATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).” Cardiovascular Drugs and Therapy, vol. 34, no. 3, Feb. 2020, pp. 357–70. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....45887ee13b195341e5d70adae8db7d93&authtype=sso&custid=ns315887.

APA

Daniel P. Judge, Arnt V. Kristen, Martha Grogan, Mathew S. Maurer, Rodney H. Falk, Mazen Hanna, Julian Gillmore, Pushkal Garg, Akshay K. Vaishnaw, Jamie Harrop, Christine Powell, Verena Karsten, Xiaoping Zhang, Marianne T. Sweetser, John Vest, & Philip N. Hawkins. (2020). Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 34(3), 357–370.

Chicago

Daniel P. Judge, Arnt V. Kristen, Martha Grogan, Mathew S. Maurer, Rodney H. Falk, Mazen Hanna, Julian Gillmore, et al. 2020. “Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (HATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).” Cardiovascular Drugs and Therapy 34 (3): 357–70. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....45887ee13b195341e5d70adae8db7d93&authtype=sso&custid=ns315887.